Brainstorm Cell Therapeutics Inc. (BCLI)

Market Cap	7.66M -13.4%
Revenue (ttm)	n/a
Net Income	-10.31M
EPS	-1.11
Shares Out	11.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,700
Open	0.6100
Previous Close	0.6300
Day's Range	0.6100 - 0.7800
52-Week Range	0.4589 - 1.3300
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company’s NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the deve...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 20
• Stock Exchange: OTCMKTS
• Ticker Symbol: BCLI